36,419 Shares in IVERIC bio, Inc. (NASDAQ:ISEE) Bought by Chartwell Investment Partners LLC

Chartwell Investment Partners LLC acquired a new position in shares of IVERIC bio, Inc. (NASDAQ:ISEE – Get Rating) during the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 36,419 shares of the company’s stock, valued at approximately $654,000.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Captrust Financial Advisors grew its position in IVERIC bio by 14,900.0% in the first quarter. Captrust Financial Advisors now owns 1,500 shares of the company’s stock valued at $25,000 after purchasing an additional 1,490 shares in the last quarter. Vectors Research Management LLC bought a new position in IVERIC bio in the second quarter valued at $29,000. Nisa Investment Advisors LLC grew its position in IVERIC bio by 39.9% in the second quarter. Nisa Investment Advisors LLC now owns 4,520 shares of the company’s stock valued at $43,000 after purchasing an additional 1,290 shares in the last quarter. Macquarie Group Ltd. grew its position in IVERIC bio by 679.5% in the second quarter. Macquarie Group Ltd. now owns 8,005 shares of the company’s stock valued at $77,000 after purchasing an additional 6,978 shares in the last quarter. Finally, Amundi bought a new position in IVERIC bio in the second quarter valued at $102,000.

Insider Buying and Selling

In related news, COO Keith Westby sold 72,916 shares of IVERIC bio stock in a transaction dated Tuesday, November 1st. The shares were sold at an average price of $23.92, for a total transaction of $1,744,150.72. Following the completion of the sale, the chief operating officer now owns 69,128 shares of the company’s stock, valued at approximately $1,653,541.76. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. In other IVERIC bio news, COO Keith Westby sold 72,916 shares of IVERIC bio stock in a transaction dated Tuesday, November 1st. The shares were sold at an average price of $23.92, for a total value of $1,744,150.72. Following the completion of the sale, the chief operating officer now owns 69,128 shares in the company, valued at approximately $1,653,541.76. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Glenn Sblendorio sold 50,000 shares of IVERIC bio stock in a transaction dated Wednesday, November 2nd. The stock was sold at an average price of $23.01, for a total transaction of $1,150,500.00. Following the completion of the sale, the chief executive officer now owns 179,689 shares of the company’s stock, valued at approximately $4,134,643.89. The disclosure for this sale can be found here. In the last 90 days, insiders sold 201,050 shares of company stock valued at $4,545,066. Company insiders own 2.70% of the company’s stock.

IVERIC bio Stock Performance

Shares of ISEE stock opened at $19.76 on Monday. The company has a quick ratio of 13.40, a current ratio of 13.40 and a debt-to-equity ratio of 0.18. The company has a 50-day simple moving average of $21.29 and a 200 day simple moving average of $16.96. IVERIC bio, Inc. has a 52 week low of $8.85 and a 52 week high of $24.33.

IVERIC bio (NASDAQ:ISEE – Get Rating) last announced its earnings results on Thursday, November 3rd. The company reported ($0.35) EPS for the quarter, topping the consensus estimate of ($0.40) by $0.05. As a group, equities analysts forecast that IVERIC bio, Inc. will post -1.43 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research firms recently weighed in on ISEE. HC Wainwright raised their target price on shares of IVERIC bio from $26.00 to $35.00 and gave the company a “buy” rating in a research report on Friday, November 4th. B. Riley raised shares of IVERIC bio from a “sell” rating to a “neutral” rating in a research report on Monday, October 17th. Jefferies Financial Group downgraded shares of IVERIC bio from a “buy” rating to a “hold” rating and decreased their price objective for the company from $30.00 to $20.00 in a research report on Thursday, November 10th. Finally, StockNews.com raised shares of IVERIC bio to a “sell” rating in a research report on Wednesday, October 5th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and seven have issued a buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $26.20.

IVERIC bio Company Profile

(Get Rating)

IVERIC bio, Inc, a biopharmaceutical company, discovers and develops novel treatments for retinal diseases with a focus on age-related and orphan inherited retinal diseases (IRDs). The company develops Zimura, an inhibitor of complement factor C5 comprising GATHER1, which has completed Phase 2/3 clinical trial; and GATHER2 that is in Phase 3 clinical trial for the treatment of geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD).